NCT01643850 - MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2012

Primary Completion Date

December 7, 2017

Study Completion Date

December 21, 2018

Conditions

Pigmented Villonodular SynovitisPVNSGiant Cell Tumor of the Tendon SheathGCCTSTenosynovial Giant Cell Tumor Localized or Diffused TypeGCTS

Interventions

DRUG

MCS110

Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.

DRUG

Placebo

Participants will receive a single dose of NaCl on day 1 through intravenous infusion.

Trial Locations (8)

4056

Novartis Investigative Site, Basel

19107

Novartis Investigative Site, Philadelphia

20011

Novartis Investigative Site, Washington D.C.

33136

Novartis Investigative Site, Miami

55455

Novartis Investigative Site, Minneapolis

60612

Novartis Investigative Site, Chicago

80237

Novartis Investigative Site, Denver

92103-8894

Novartis Investigative Site, San Diego